Crism Therapeutics (LSE:CRTX) YoY EBITDA Growth : 100.01% (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Crism Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Crism Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 100.01%.

Crism Therapeutics's EBITDA per Share for the six months ended in Jun. 2024 was £0.00.

Crism Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Crism Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crism Therapeutics YoY EBITDA Growth Chart

Crism Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

36.06

-9.40

47.08

-37.01

3.32

Crism Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
YoY EBITDA Growth	Get a 7-Day Free Trial															-68.04	14.04	-4,156.44	-287.76	100.01

Crism Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Crism Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.204	-	-0.211)	/	\| -0.211 \|
=	3.32 %

Crism Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

	YoY EBITDA Growth (Q: Jun. 2024 )
=	(EBITDA per Share (Q: Jun. 2024 )	-	EBITDA per Share (Q: Jun. 2023 ))	/	\| EBITDA per Share (Q: Jun. 2023 )) \|
=	(0.001	-	-6.938)	/	\| -6.938 \|
=	100.01 %

Crism Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Crism Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Crism Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Metals & Mining » Crism Therapeutics Corp (LSE:CRTX) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB

Website

https://www.crismtherapeutics.com

Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.

Crism Therapeutics Headlines

No Headlines